Skip to main content

Table 6 Improvement in functioning and patient impression of illness improvement

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

 

Galcanezumab 120 mg

Galcanezumab 240 mg

N

Mean (SE) or %

N

Mean (SE) or %

MSQ RF-R, mean increase (improvement)

130

31.6 (1.2)

135

33.4 (1.2)

MIDAS total, mean decrease (improvement)

124

−33.6 (2.1)

130

−32.7 (2.0)

Patient Global Impression – Illness Improvement at Month 12

90

–

112

–

 Very much better

 

52.2%

 

52.7%

 Much better

 

27.8%

 

32.1%

 A little better

 

15.6%

 

7.1%

 No change

 

3.3%

 

7.1%

 A little worse

 

1.1%

 

0.9%

 Much worse

 

0%

 

0%

 Very much worse

 

0%

 

0%

  1. MIDAS Migraine Disability Assessment, MSQ RF-R Migraine-Specific Questionnaire Role Function – Restrictive, SE standard error